{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T13:17:03.340954",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 61,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "overall survival (time from randomization to death from any cause)",
        "prolonged survival",
        "event-free survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (independent review panel, RECIST 1.1)",
        "progression-free survival (sensitivity analysis considering initiation of new anti-cancer therapy as event)",
        "progression-free survival (measured by time to death)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1; blinded independent central review)",
        "objective response rate (independent review committee, RECIST 1.1)",
        "objective response rate (RECIST 1.1)",
        "overall response rate (ORR)",
        "overall response rate",
        "response rates",
        "complete response (RECIST 1.1)",
        "partial response (RECIST 1.1)",
        "disease control rate",
        "disease control rate (proportion with complete, partial, or stable disease for at least 5 weeks)",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "time to response",
        "time to response (from treatment initiation to first complete or partial response)",
        "treatment duration",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment",
        "dropout rate",
        "adverse event rate",
        "serious adverse event rate",
        "grade 3-4 adverse event rate",
        "mortality-related toxicity",
        "treatment discontinuation",
        "treatment discontinuation due to adverse events"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events",
        "adverse events (general)",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events grade 3 or higher",
        "adverse drug reactions",
        "side effects (PRO-CTCAE instrument)",
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious undesirable effects",
        "serious side effects on the skin",
        "severe adverse events",
        "interstitial lung disease (severe adverse event)",
        "liver disorders (severe adverse event)",
        "stomatitis (adverse event)",
        "peripheral oedema (adverse event)",
        "peripheral neuropathy (adverse event)",
        "alopecia (adverse event)",
        "blood and lymphatic system disorders (adverse event)",
        "fatigue (adverse event)",
        "fatigue",
        "fever (adverse event)",
        "fever",
        "infections and infestations (adverse event)",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "febrile neutropenia"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse events",
        "serious undesirable effects",
        "serious side effects on the skin",
        "interstitial lung disease (severe adverse event)",
        "liver disorders (severe adverse event)",
        "febrile neutropenia"
      ],
      "discontinuations": [
        "discontinuation due to adverse events",
        "treatment discontinuation",
        "treatment discontinuation due to adverse events",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "item GP5 of the FACT-G",
        "PGI-C",
        "PGIC",
        "PGIS",
        "EQ-5D VAS",
        "EQ-5D-5L",
        "NSCLC-SAQ",
        "PRO-CTCAE",
        "visual analogue scale (progression-free health state)"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology (EORTC QLQ-C30)",
        "symptom control",
        "changes in cancer-specific symptoms (patient-reported outcome measures)",
        "changes in overall health status (patient-reported outcome measures)",
        "health status (EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, EQ-5D VAS)",
        "health-related quality of life",
        "health-related quality of life (EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C, EQ-5D VAS)",
        "health-related quality of life (measured by time to death)",
        "preservation of quality of life",
        "overall health status",
        "physical benefits",
        "psychological benefits"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle of treatment",
        "progression-free survival utility",
        "progression-free survival on-treatment utility differential",
        "health-state utility",
        "time-to-death utility"
      ],
      "resource_utilization": [
        "duration of treatment"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "side effects (PRO-CTCAE instrument)"
      ],
      "biomarkers": []
    }
  }
}